VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce the acceptance of a new abstract to be presented at the 2022 AACR Annual Meeting.
Read more at globenewswire.comRakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
